BEIJING, China, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Zhihu Inc. ("Zhihu" or the "Company") (NYSE:ZH, HKEX: 2390)), a leading online content community in China, today announced that the Company, through a wholly owned subsidiary, has entered into a subscription agreement for a limited partnership interest in Tianjin Lisi Xingshen Equity Investment Partnership (Limited Partnership) (the "Fund"), subject to approval by the Company’s shareholders at an extraordinary general meeting ("EGM"). The proposed subscription involves a capital commitment of RMB1.5 billion, payable in cash pursuant to the Fund’s capital call arrangements. The Company expects that its interest in the Fund will be no more
Press Releases
Delayed 3mFastest customizable press release feed in the world.
Signed out · 3-min delay · Sign up for real-time
- Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund
- Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (NASDAQ:ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Mosli
- Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00 a.m. ET on Tuesday, September 8, 2026. To
- Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i
At a glance Customer relief offer: We are waiving calling, texting and data charges on Kaua’i to help our consumer and small business customers connect with loved ones.Strengthened network infrastructure: We have prepared our Hawai’i network with backup generators, satellite assets, and pre-staged equipment designed for reliability during severe weather.Satellite messaging: Verizon customers can maintain essential communications via satellite, allowing compatible phones to send text messages or connect with emergency services.Proactive collaboration: We are working directly with the Hawai’i Emergency Management Agency (HIEMA), local power providers, and public safety officials to support cr
- Tuya Smart Brings Full-Stack AI into Everyday Life at IFA 2026
BERLIN, Sept. 5, 2026 /PRNewswire/ -- Tuya Smart (NYSE:TUYA, HKEX: 2391)), a global AI cloud platform service provider, is showcasing its latest advances in physical AI at IFA 2026 under the theme "Hey Tuya." Headlining the exhibit is the global debut of the new AI companion robot Doova, alongside the European debut of Tuya's AI Home, AI Energy, and AI Robot ecosystems, the Hey Tuya whole-space intelligent interaction experience, a full-stack Matter portfolio, and development tools designed to help turn AI hardware concepts into working products. The showcase illustrates how Tuya is connecting cloud intelligence, devices, and developer tools to move AI beyond screens and into practi
- Tuya Smart Unveils Doova at IFA 2026, an AI Home Companion Robot Designed to Support Independently Living Seniors
BERLIN, Sept. 5, 2026 /PRNewswire/ -- Tuya Smart (NYSE:TUYA, HKEX: 2391)), a global AI cloud platform service provider, today unveiled Doova, its new AI home companion robot, at IFA 2026. Designed for seniors living alone, Doova moves beyond the traditional roles of security devices and household robots, combining proactive safety protection, emotionally intelligent companionship, and seamless smart home coordination to support a safer, more connected, and more comfortable daily life.For many seniors living independently, the greatest concern is not simply an accident itself, but the time that passes before anyone realizes something is wrong.Doova is equipped with LDS LiDAR, a four-microphon
- Marcus & Millichap’s IPA Capital Markets Arranges $75.1 Million Recapitalization for The Monroe Hotel in Miami Beach’s Faena District
IPA Capital Markets, a division of Marcus & Millichap (NYSE:MMI) specializing in capital markets services for major private and institutional clients, announced today the $75.1 million mid-construction recapitalization of The Monroe Hotel, an 89-key luxury boutique hotel under redevelopment at 3010 Collins Ave. in Miami Beach’s Faena District.Bobby Werhane, managing director with IPA Capital Markets, led the transaction on behalf of the property’s ownership group, with support from Scott Raasch, IPA Capital Markets senior director, both based in the firm’s Charlotte office. The team structured a capital stack comprising four sources, two of which represented new lending relationships for the
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector Sept 21, 2026 S&P 100AdditionDell Techno
- Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical con
- ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation Innovative treatment strategy has potential to reshape 1st-line treatment paradigm for patients in this setting AstraZeneca’s ETCAMAH® (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, ba
- Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025
GUADALAJARA, Mexico, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE:PAC, BMV:GAP) ("the Company" or "GAP") announces preliminary terminal passenger traffic figures for August 2026, compared with August 2025. During August 2026, the 12 Mexican airports operated by GAP recorded a 2.6% increase in total passenger traffic compared to August 2025. Guadalajara and Tijuana airports reported an increase of 10.5% and 1.2%, respectively, while Puerto Vallarta and Los Cabos airports reported a decrease of 10.3% and 6.2%, respectively, compared to August 2025. With respect to GAP’s airports in Jamaica, Kingston airport recorded an increase of 2.8%, while Mo
- Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported. Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will now participate in a fireside chat session at 10:15 a.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and servic
- Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
Approval recommends repeat Guardant360 CDx testing every three months during therapy to detect emerging ESR1 mutations before clinical or radiographic disease progressionIn the Phase III SERENA-6 trial, ctDNA-guided treatment using Guardant360 CDx with camizestrant plus a CDK4/6 inhibitor following detection of an ESR1 mutation reduced the risk of disease progression or death by 56%Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harbor
- BMO Completes Sale of 138 U.S. Branches to First Citizens Bank
TORONTO and CHICAGO, Sept. 4, 2026 /CNW/ -- BMO Financial Group (TSX:BMO) (NYSE:BMO) today announced the completion of the sale of 138 branches to First-Citizens Bank & Trust Company ("First Citizens Bank"). As previously announced, the branches are in North Dakota, South Dakota, Wyoming, Nebraska, Kansas, Missouri, Oklahoma, and Idaho, as well as select branches in Minnesota, Oregon, and Illinois.The transaction supports BMO's strategy to optimize its U.S. financial center network and redeploy capital and resources to markets with strong client engagement and long-term growth potential.About BMO Financial Group BMO Financial Group is the eighth largest bank in North America by assets, with
- Alpha Compute Corp. Market Update
New York, NY, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alpha Compute Corp. (NASDAQ:ALP) ("Alpha Compute" or the "Company"), a technology company scaling global AI infrastructure and digital assets, today issued a comprehensive market update to its shareholders, highlighting its rapidly expanding cash flows, deep sales pipeline, and recent operational milestones achieved over the past 60 days. The executive leadership emphasizes that the Company faces no unannounced operational challenges or undisclosed material concerns. Fully focused on execution, Company management considers Alpha Compute significantly undervalued relative to its strong balance sheet assets, accelerating annual recurring cash
- HII Details Strategy to Increase Shipbuilding Pace for U.S. Navy
SANTA CLARITA, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- HII’s (NYSE:HII) executive vice president of maritime systems and corporate strategy, Eric Chewning, reaffirmed the company’s commitment to strengthening the nation’s defense industrial base and revitalizing U.S. shipbuilding today during a House Appropriations Subcommittee on Defense field hearing. Speaking at College of the Canyons before subcommittee Chairman Rep. Ken Calvert, and members of the subcommittee, Chewning underscored the critical importance of a modernized workforce, upgraded shipyard infrastructure, and an expanded maritime industrial base. "America’s ability to maintain peace and defend our interests depends on a
- Laird Superfood Appoints Mark Johnson as Chief Financial Officer
Seasoned CPG finance executive brings more than 25 years of experience across beverage, food, and premium pet food.Laird Superfood, Inc. (NYSE:LSF) today announced the appointment of Mark Johnson as Chief Financial Officer, effective October 1, 2026. Mr. Johnson will report to Chief Executive Officer Jason Vieth and will serve as the Company’s principal financial officer and principal accounting officer.Mr. Johnson brings more than 25 years of finance leadership across public consumer packaged goods and private equity-backed companies. He joins Laird Superfood from Tropicana Brands Group, where he served as Vice President of Finance – North America. Previously, he was Vice President – Commer
- Phaos Technology Holdings (Cayman) Limited Announces Results of Extraordinary General Meeting
SINGAPORE, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited, (NYSE:POAS), ("Phaos" or "the Company"), an advanced microscopy solutions headquartered in Singapore, today announced the results of its extraordinary general meeting of shareholders (the "Extraordinary General Meeting"), which was held on August 31, 2026 at 9:30 p.m. Singapore Time (9:30 a.m. Eastern Time). A quorum of shareholders was present in person or by proxy, and the Extraordinary General Meeting was duly constituted. Each of the proposals set out in the Company’s notice of meeting and proxy statement dated August 12, 2026 was put to a vote and was duly approved by the requisite majority of s
- Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026, in New York, NY. Company management will also be available for one-on-one meetings with investors. Conference DetailsEvent: H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date and Time: Monday, September 14, 2026, 3:00 – 3:30 p.m. ETLocation: New York, NYRegist
- Crane NXT to Participate in the 2026 Jefferies Global Industrial Conference
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE:CXT) ("Crane NXT" or the "Company"), a global leader in authentication and traceability technologies, today announced it will participate in the 2026 Jefferies Global Industrial Conference on Thursday, September 10, 2026. The conference will include a fireside chat with Aaron Saak, President and Chief Executive Officer and Christina Cristiano, Senior Vice President and Chief Financial Officer which will be held at 1:30p.m. Eastern Time. Participants may access the live webcast through the Investors section of Crane NXT’s website at www.cranenxt.com. An archived replay will be available on the company’s website after t